Abvc Biopharma (ABVC) EBITDA Margin (2010 - 2025)
Abvc Biopharma's (ABVC) quarterly EBITDA Margin came in at 287.75% in Q4 2025, up 3612519.0% YoY from N/an in Q4 2024, and up 100.8% on a QoQ basis from 35837.44% in Q4 2024.
Abvc Biopharma (ABVC) EBITDA Margin (2010 - 2025) Analysis & Trends
Abvc Biopharma (ABVC) has 13 years of EBITDA Margin data on file, last reported at 287.75% in Q4 2025.
- Quarterly EBITDA Margin rose 3612519.0% year-over-year to 287.75% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 2795.79% (up 371913.0% YoY) and the FY2025 annual result came in at 22503.1%, down 2157976.0% from the prior year.
- EBITDA Margin grew to 287.75% in Q4 2025, from 35837.44% in the prior quarter.
- In the past five years, EBITDA Margin ranged from a high of 1638.04% in Q4 2021 to a low of 235539.83% in Q1 2024.
- A 5-year average of 22824.79% and a median of 1990.48% in 2021 frame the typical range for EBITDA Margin.
- Annual changes were most pronounced in 2024 — EBITDA Margin sank 23405379 bps — and 2025, when it surged 3612519 bps.
- Tracing ABVC's EBITDA Margin over 5 years: stood at 1638.04% in 2021, then sank by 132 bps to 531.92% in 2022, then tumbled by 4345 bps to 23641.34% in 2023, then tumbled by 52 bps to 35837.44% in 2024, then jumped by 101 bps to 287.75% in 2025.
- The last three EBITDA Margin figures came in at 287.75% (Q4 2025), 35837.44% (Q4 2024), and 77.66% (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 17.93% |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -0.36% |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.75% |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -35.57% |
| 10 | Abvc Biopharma | 23.34 Mn | 23.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 287.75% |
| Dec 31, 2024 | -35,837.44% |
| Sep 30, 2024 | -77.66% |
| Jun 30, 2024 | -734.24% |
| Mar 31, 2024 | -235,539.83% |
| Dec 31, 2023 | -23,641.34% |
| Sep 30, 2023 | -13,566.31% |
| Jun 30, 2023 | -35,911.64% |
| Mar 31, 2023 | -1,486.05% |
| Dec 31, 2022 | -531.92% |
| Sep 30, 2022 | -8,790.94% |
| Jun 30, 2022 | -654.24% |
| Mar 31, 2022 | -24,235.08% |
| Dec 31, 2021 | 1,638.04% |
| Sep 30, 2021 | -1,990.48% |
| Jun 30, 2021 | -6,474.08% |
| Mar 31, 2021 | -476.06% |
| Dec 31, 2020 | -7,799.30% |
| Sep 30, 2020 | -1,116.17% |
| Jun 30, 2020 | -527.13% |